The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Pfizer's new and recently acquired products generated 22% operational growth in Q1. The company faces a challenging road ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.

On Tuesday, Vice Chancellor Morgan T. Zurn and U.S. District Judge Maryellen Noreika signed off on dismissal of a breach of contract case and an antitrust action, respectively, both of which Pfizer ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near ...

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.

Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...